Browse by category

The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The British Medical Journal (BMJ) has reported. Although the absolute risk is low, awareness of this potential effect may help inform shared treatment decisions, according to the study’s researchers from the University of Pennsylvania, Philadelphia, PA. Alopecia has b

Two separate studies have report that GLP-1s are linked to fewer alcohol and substance related hospitalisations for people with alcohol or substance use dependence. In the first study, published in The Lancet Psychiatry, people with type 2 diabetes were hospitalised less frequently for alcohol or substance use disorders while undergoing treatment with GLP-1 receptor agonists, according to a large Swedish registry study involving the Central Institute of Mental Health (CIMH).

For patients undergoing body contouring surgery to remove excess abdominal skin after significant weight loss, use of GLP-1 weight-loss medications may have mixed effects on complication risks, according to a study by researchers from West Virginia University School of Medicine, Morgantown, WV. Share of all patients who take a GLP-1 RA by state. Credit: Plastic & Reconstructive Surgery (2025). DOI: 10.1097/prs.0000000000012405 "As GLP-1 receptor agonist (GLP1ra) medications b

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may significantly improve post-surgical outcomes for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and obesity, according to a study led by Cleveland Clinic researchers. At one-year follow-up, patients taking GLP-1RAs showed a 36% reduction in the need for revision sinus surgery. Additionally, at five years post-surgery, patients experienced a 40% reduction in revision surgery rates and a 28% decrease in f

A systematic review and meta-analysis that evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity, has found that the drugs probably have little or no effect on risk for thyroid, pancreatic, breast, or kidney cancer and may have little or no effect on other obesity-related cancers. However, the researchers from Harvard Medical School stated the certainty

In a major new study, researchers from Intermountain Health in Salt Lake City have found that GLP-1 receptor agonists used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events, and for those who have never had pancreatitis, being on a GLP1RA medication led to a four times lower risk of developing the condition. "Pancreatitis is incredibly painful and can be deadly. Once you have a patient with acute pancreatitis, you wan

There has been a 16-fold increase in the use of weight loss drugs among patients before metabolic and bariatric surgery, signalling an...

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo metabolic and bariatric surgery (MBS)...

A study led by investigators at Mass General Brigham has found that adding semaglutide and tirzepatide to usual care represents a...

Some individuals who are taking Ozempic, Wegovy or Mounjaro find that foods taste sweeter or saltier than before, according to research...